基于突变选择窗理论的新型药代动力学/药效学模型的研究进展  

Research progress of a new pharmacokinetics/pharmacodynamic model based on the theory of mutant selection windows

作　　者：张晗 柏长青[1] 牛文凯[1] 苑鑫[1] 

机构地区：[1]中国人民解放军第307医院呼吸与危重症医学科,北京100071

出　　处：《中国临床药理学杂志》2018年第1期89-91,共3页The Chinese Journal of Clinical Pharmacology

基　　金：国家自然科学基金青年基金资助项目(81400009)

摘　　要：目前,因为抗生素过度使用而导致的耐药菌株蔓延问题得到了广泛的关注。以防耐药突变浓度(MPC)和突变选择窗(MSW)理论为基础的新型药代动力学/药效学(PK/PD)模型,与旧的模型相比,可以通过关闭或缩小突变选择窗的方式有效地防止耐药突变菌株的产生。本文围绕突变选择窗、防耐药突变浓度的基本概念和原理及其在指导新型PK/PD模型建立方面的应用展开综述,为该模型在指导抗生素药物的合理应用及遏制耐药突变菌的出现提供一定的参考依据。At present,more attention has been paid to the spread of drug-resistant strains caused by the abuse of antibiotics. Comparing to the old model,the new model of pharmacokinetic/pharmacodynamic（ PK/PD） which were based on the theory of mutant prevention concentration（ MPC） and mutant selection window（ MSW）,can effectively prevent the emergence of drug-resistant strains by the way of closing or reducing MSW. In this review,we summarized the basic concept and theory of MSW,MPC as well as its application in guiding the establishment of new PK/PD model,hoping to provide references for the rational use of antibiotics and inhibiting the emergence of drug-resistant mutant strains.

关 键 词：防耐药突变浓度 突变选择窗 药代动力学/药效学 临床用药 

分 类 号：R978.1[医药卫生—药品]